相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selection bias in rheumatic disease research
Hyon K. Choi et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
The challenges of comparing results between placebo controlled randomized trials and non-experimental new user, active comparator cohort studies: the example of olmesartan
Wendy Camelo Castillo et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
The incident user design in comparative effectiveness research
Eric S. Johnson et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Diagnosing and responding to violations in the positivity assumption
Maya L. Petersen et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2012)
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development
S. Schneeweiss et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Carlos G. Grijalva et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
The Identification of Frailty: A Systematic Literature Review
Shelley A. Sternberg et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2011)
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Minimizing Bias Due to Confounding by Indication in Comparative Effectiveness Research The Importance of Restriction
Bruce M. Psaty et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
Anja Strangfeld et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes
Linda E. Levesque et al.
BRITISH MEDICAL JOURNAL (2010)
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor α Therapies Does the Risk Change With the Time Since Start of Treatment?
Johan Askling et al.
ARTHRITIS AND RHEUMATISM (2009)
Dealing with limited overlap in estimation of average treatment effects
Richard K. Crump et al.
BIOMETRIKA (2009)
Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies
Enrique F. Schisterman et al.
EPIDEMIOLOGY (2009)
Mortality reduction with influenza vaccine in patients with pneumonia outside Flu season - Pleiotropic benefits or residual confounding?
Dean T. Eurich et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis -: Lessons from interpreting data from observational studies
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2007)
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
Jeffrey R. Curtis et al.
ARTHRITIS AND RHEUMATISM (2007)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Pharmacoepidemiology and rheumatic disorders
KA Chan et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2004)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Paradoxical relations of drug treatment with mortality in older persons
RJ Glynn et al.
EPIDEMIOLOGY (2001)
分享论文
